Moreover, LG268 increases both expression of PD-L1 in macrophages and tumor-suppressive immune cell populations within the tumor microenvironment, creating a favorable milieu for the combination of appropriate RXR agonists with anti-PDL-1 antibodies. This evidence concerns the gene CD274 and neoplasm.